TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39113067

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (when LDL-C < 70 mg/dL)
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Atorvastatin (when LDL-C < 70 mg/dL)
Number of subjects: 2377
Study: 39113069

Group type: COMPARATOR
Intervention: Adult donor-RBCs (A-RBCs)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Allogeneic CB-RBCs
Number of subjects: 146
Study: 39113112

Group type: EXPERIMENTAL
Intervention: Panfungal-PCR screening methods
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Repeated testing and fungal genus identification by Sanger sequencing
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Panfungal-PCR screening
Number of subjects: 195
Study: 39113181

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) 3 times per week, consisting of 10×1 minute at 80%-100% heart rate reserve interspersed with 1 minute at 30% heart rate reserve (totaling 19 minutes)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) 3 times per week, consisting of 20-30 minutes at 40%-60% heart rate reserve
Number of subjects: 82
Study: 39113190

Group type: EXPERIMENTAL
Intervention: Neoadjuvant AC-T chemotherapy with metformin
Number of subjects: 70
Study: 39113266

Group type: EXPERIMENTAL
Intervention: Mobile application for urinary incontinence treatment
Number of subjects: 10
Study: 39114274

Group type: EXPERIMENTAL
Intervention: Sutimlimab (C1s inhibitor), biweekly doses for up to 1 year after Part A
Number of subjects: 39
Study: 39114536

Group type: EXPERIMENTAL
Intervention: THC alone
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: CBD alone
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: THC/CBD combination
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: THC alone, CBD alone, THC/CBD combination, Placebo
Number of subjects: 250
Study: 39114670

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 118

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 118
Study: 39114821

Group type: EXPERIMENTAL
Intervention: Multi-organ, multi-parametric magnetic resonance imaging (MRI) and circulating biomarkers
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Aerobic endurance (6 min walk test)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Cognition testing
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Olfaction assessment
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Clinical outcomes collected up to 1 year from infection
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Imaging and circulating biomarkers
Number of subjects: 215

Group type: COMPARATOR
Intervention: Comparison to controls (133 healthy volunteers)
Number of subjects: 215
Study: 39114823

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 100
Study: 39114870

Group type: EXPERIMENTAL
Intervention: Zanidatamab treatment (administered once every 2 weeks)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Zanidatamab treatment
Number of subjects: 87
Study: 39114916

Group type: EXPERIMENTAL
Intervention: Erythritol (30 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose (30 g)
Number of subjects: 20
Study: 39115062

Group type: EXPERIMENTAL
Intervention: Nipocalimab (30 or 45 mg per kilogram of body weight per week) administered from 14 to 35 weeks' gestation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nipocalimab treatment
Number of subjects: 13
Study: 39115122

Group type: EXPERIMENTAL
Intervention: Transverse extraction site closure
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Vertical extraction site closure
Number of subjects: 1356
Study: 39115302

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39115419

Group type: EXPERIMENTAL
Intervention: mRNA-4157 (1-mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: mRNA-4157 (1-mg) + Pembrolizumab (200-mg)
Number of subjects: 16
Study: 39115479

Group type: EXPERIMENTAL
Intervention: Post-PCI angio-IMR >25
Number of subjects: 2212

Group type: COMPARATOR
Intervention: Post-PCI angio-IMR ≤25
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Post-PCI angio-IMR
Number of subjects: 2212
Study: 39115551

Group type: EXPERIMENTAL
Intervention: NPSLE
Number of subjects: 3545
Study: 39115583

Group type: EXPERIMENTAL
Intervention: Dextrose Prolotherapy and Deep Dry Needling (DDN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Deep Dry Needling (DDN)
Number of subjects: 40
Study: 39115608

Group type: EXPERIMENTAL
Intervention: Community-based intervention (information campaigns on AF diagnosis and therapies)
Number of subjects: 2769

Group type: COMPARATOR
Intervention: Control group (recruited prior to intervention)
Number of subjects: 2769
Study: 39115709

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Low MASCC-score
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Colonisation with Pichia kudriavzevii
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Quinolone use
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Citrulline level
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Active chronic obstructive pulmonary disease
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Colonisation with fluconazole-resistant Candida
Number of subjects: 416
Study: 39115845

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) with usual oncological care
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual supportive oncological care
Number of subjects: 144
Study: 39115975

Group type: EXPERIMENTAL
Intervention: Hypofractionated (HF) PMRT (4256 cGy for 16 fractions)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Hypofractionated (HF) PMRT
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventionally Fractionated (CF) PMRT (5000 cGy for 25 fractions)
Number of subjects: 400
Study: 39116012

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (RiaSTAP; CSL Behring)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cryoprecipitate (control group)
Number of subjects: 36
Study: 39116013

Group type: EXPERIMENTAL
Intervention: Assisted Fluid Management (AFM) guided GDFT
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard GDFT
Number of subjects: 86
Study: 39116153

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine therapy
Number of subjects: 30
Study: 39116333

Group type: EXPERIMENTAL
Intervention: CETA-PWH (transdiagnostic counseling intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CETA-PWH (moderate dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CETA-PWH (completers)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CETA-PWH and Usual care
Number of subjects: 60
Study: 39116385

Group type: EXPERIMENTAL
Intervention: Exaggerated maximal systolic BP (SBPmax) defined as ≥210 mmHg in males and ≥190 mmHg in females
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Mean SBP/W-slope
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Peak oxygen uptake (VO2peak)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Exaggerated SBPmax and below-median SBP/W-slope
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Non-exaggerated SBPmax and above-median SBP/W-slope
Number of subjects: 589
Study: 39116386

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39116423

Group type: EXPERIMENTAL
Intervention: PARITY intervention (wellness technology platform and community doula support)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PARITY intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Informational control group
Number of subjects: 60
Study: 39116435

Group type: EXPERIMENTAL
Intervention: Brain training program (BrainHQ by Posit Science)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Active control program (computer games designed for entertainment, e.g., Solitaire)
Number of subjects: 93
Study: 39116443

Group type: EXPERIMENTAL
Intervention: Virtual video postoperative visit
Number of subjects: 100

Group type: COMPARATOR
Intervention: In-office postoperative visit
Number of subjects: 100
Study: 39116448

Group type: EXPERIMENTAL
Intervention: XGBoost
Number of subjects: 4077

Group type: EXPERIMENTAL
Intervention: ML models (eXtreme Gradient Boosting, Feedforward Neural Network, Logistic Regression, Support Vector Machine)
Number of subjects: 4077

Group type: EXPERIMENTAL
Intervention: Histological features identified by the Banff criteria
Number of subjects: 4077
Study: 39116451

Group type: EXPERIMENTAL
Intervention: AI-based model for measuring preoperative kidney cortex volume from CT images
Number of subjects: 1074

Group type: EXPERIMENTAL
Intervention: Elderly donors
Number of subjects: 1074
Study: 39116486

Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine (IIV4) - three manufacturing lots, single dose.
Number of subjects: 1260
Study: 39116661

Group type: EXPERIMENTAL
Intervention: Kahoot games and augmented reality (AR)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 410
Study: 39116683

Group type: EXPERIMENTAL
Intervention: Olaparib plus trastuzumab
Number of subjects: 5
Study: 39116902

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan 5·4 mg/kg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan 6·4 mg/kg
Number of subjects: 122
Study: 39116904

Group type: EXPERIMENTAL
Intervention: Butantan-DV (0.5 mL single dose)
Number of subjects: 16235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16235
Study: 39117359

Group type: EXPERIMENTAL
Intervention: Deep learning model for detection of glaucoma progression
Number of subjects: 134

Group type: COMPARATOR
Intervention: Logistic regression model for detection of glaucoma progression
Number of subjects: 134
Study: 39117402

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) using Freestyle Libre ProIQ device
Number of subjects: 100
Study: 39117404

Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Regular treadmill walking (control)
Number of subjects: 140
Study: 39117412

Group type: EXPERIMENTAL
Intervention: Dynamic arterial elastance (EaDyn) for weaning vasopressor support
Number of subjects: 114

Group type: COMPARATOR
Intervention: Mean arterial pressure (MAP) for weaning vasopressor support
Number of subjects: 114
Study: 39117415

Group type: EXPERIMENTAL
Intervention: 81 mg daily aspirin
Number of subjects: 15076

Group type: COMPARATOR
Intervention: 325 mg daily aspirin
Number of subjects: 15076

Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 15076
Study: 39117445

Group type: EXPERIMENTAL
Intervention: Bio-induction-CS (adding etanercept for 24 weeks)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard-CS (adding leflunomide first)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Bio-induction-CS
Number of subjects: 110
Study: 39117488

Group type: EXPERIMENTAL
Intervention: PEG-EPO (0.2, 0.4, 0.8, 1.6, 2.4, 3.6, or 4.8 µg/kg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: PEG-EPO
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 39117670

Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg iv on day 1, carboplatin AUC 5 iv on day 1, etoposide 100 mg/m2 iv on days 1-3
Number of subjects: 0
Study: 39117964

Group type: EXPERIMENTAL
Intervention: Glibenclamide 3.75 mg/day for 7 days
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study: 39118020

Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures
Number of subjects: 25

Group type: COMPARATOR
Intervention: Complete dentures
Number of subjects: 25
Study: 39118035

Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity coaching (5 sessions: 1 pre and 4 post surgery, intervention resource manual, wristband pedometer)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Physical activity self-monitoring alone (ASCO physical activity information, wristband pedometer)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity coaching
Number of subjects: 382

Group type: COMPARATOR
Intervention: Physical activity self-monitoring alone
Number of subjects: 382
Study: 39118070

Group type: EXPERIMENTAL
Intervention: Phase-change-material mattress (PCM)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control (without PCM)
Number of subjects: 113
Study: 39118082

Group type: EXPERIMENTAL
Intervention: Apple Vinegar
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ethylene diamine tetraacetic acid (17%) for five minutes
Number of subjects: 40
Study: 39118095

Group type: EXPERIMENTAL
Intervention: Antral membrane balloon technique
Number of subjects: 22

Group type: COMPARATOR
Intervention: Densah burs
Number of subjects: 22
Study: 39118135

Group type: EXPERIMENTAL
Intervention: robotic-assisted transabdominal preperitoneal (rTAPP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: laparoscopic TAPP
Number of subjects: 150
Study: 39118136

Group type: EXPERIMENTAL
Intervention: EMPATIA program (8-week guided Internet-delivered indicated prevention program)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Care as usual (CAU) control condition
Number of subjects: 152
Study: 39118150

Group type: EXPERIMENTAL
Intervention: Pozelimab
Number of subjects: 10
Study: 39118161

Group type: EXPERIMENTAL
Intervention: CCM-C training program (immediate intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-list control (receiving CCM-C approximately 6 weeks later)
Number of subjects: 100
Study: 39118264

Group type: EXPERIMENTAL
Intervention: Trans-nonachlor
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: cis-nonachlor
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Mirex
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 4,4 DDE
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Positive samples of organochlorines in fat
Number of subjects: 2

Group type: COMPARATOR
Intervention: Urine samples
Number of subjects: 2
Study: 39118360

Group type: COMPARATOR
Intervention: Twice-daily use of 0.454% stannous fluoride (SnF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Experimental group (frequency of bioavailable SnF not specified)
Number of subjects: 90
Study: 39118415

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Chelation therapy
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: History of iron overload
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Treatment interventions for neonatal complications
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Osteopenia/osteoporosis
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Thromboembolic events
Number of subjects: 241
Study: 39118424

Group type: EXPERIMENTAL
Intervention: Nurse parental support using a symptom management mobile app for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care available in the community
Number of subjects: 0
Study: 39118878

Group type: EXPERIMENTAL
Intervention: 3D lung reconstructions using open-source software
Number of subjects: 13
Study: 39119004

Group type: EXPERIMENTAL
Intervention: Lugol's solution 5%, three oral drops thrice daily for 10 days
Number of subjects: 20
Study: 39119627

Group type: EXPERIMENTAL
Intervention: People living with obesity (PLwO)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs)
Number of subjects: 8000
Study: 39119698

Group type: EXPERIMENTAL
Intervention: Higher concentrations of trimethylamine
Number of subjects: 11768
Study: 39119705

Group type: EXPERIMENTAL
Intervention: Evening binge alcohol consumption
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fluid control
Number of subjects: 26
Study: 39119911

Group type: EXPERIMENTAL
Intervention: Zolpidem-ER
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 39119917

Group type: EXPERIMENTAL
Intervention: hs-cTnT (Roche Diagnostics)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: hs-cTnI (Siemens Healthineers)
Number of subjects: 754
Study: 39119964

Group type: EXPERIMENTAL
Intervention: IVT plus DAPT
Number of subjects: 240

Group type: COMPARATOR
Intervention: DAPT alone
Number of subjects: 240
Study: 39119981

Group type: EXPERIMENTAL
Intervention: Study pacifier
Number of subjects: 451

Group type: COMPARATOR
Intervention: Non-study pacifier
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Digit sucking for 12 months or more
Number of subjects: 451
Study: 39120078

Group type: COMPARATOR
Intervention: Level 1 (health education+objective monitoring, n=26)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Level 2 (asynchronous contact, level 1+prerecorded exercise videos, n=30)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Level 3 (synchronous contact, level 1+videoconference group exercise, n=28)
Number of subjects: 84
Study: 39120779

Group type: EXPERIMENTAL
Intervention: Project Think (Cognitive Restructuring Digital Mental Health Intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Project Share (Supportive Therapy)
Number of subjects: 0
Study: 39120786

Group type: EXPERIMENTAL
Intervention: LEM 5 mg (Study 304)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: LEM 10 mg (Study 304)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Zolpidem tartrate extended-release 6.25 mg (Study 304)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Placebo (Study 304)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: LEM 5 mg (Study 106)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: LEM 10 mg (Study 106)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Placebo (Study 106)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Zolpidem (Study 108)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: LEM 5 mg (Study 108)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Placebo (Study 108)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: LEM (all doses)
Number of subjects: 1006
Study: 39120847

Group type: EXPERIMENTAL
Intervention: Adalimumab-adbm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab reference product
Number of subjects: 0
Study: 39120848

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks (Q4W)
Number of subjects: 1435
Study: 39120850

Group type: EXPERIMENTAL
Intervention: Adalimumab-adbm (Cyltezo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab Reference Product
Number of subjects: 0
Study: 39120849

Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 698

Group type: COMPARATOR
Intervention: Risankizumab
Number of subjects: 698
Study: 39120895

Group type: EXPERIMENTAL
Intervention: Immediate practice facilitation
Number of subjects: 11789

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 11789

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11789
Study: 39120901

Group type: EXPERIMENTAL
Intervention: Salt-based nicotine e-liquids
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 1% nicotine e-liquids
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Menthol-flavored e-liquids
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5% nicotine e-liquids
Number of subjects: 72
Study: 39120902

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for insomnia integrated in best-evidence pain management (CBTi-BEPM)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Best-evidence pain management only (BEPM)
Number of subjects: 123
Study: 39121101

Group type: EXPERIMENTAL
Intervention: Tobbstop app (adapted for pregnant women)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Focus groups and individual interviews
Number of subjects: 10
Study: 39121163

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 11
Study: 39121437

Group type: EXPERIMENTAL
Intervention: Revumenib
Number of subjects: 94
Study: 39121442

Group type: EXPERIMENTAL
Intervention: Genomic subtype analysis in children with standard-risk ALL
Number of subjects: 1381

Group type: EXPERIMENTAL
Intervention: Genetic subtype, patterns of aneuploidy, and secondary genomic alterations
Number of subjects: 1381

Group type: EXPERIMENTAL
Intervention: Comprehensive genomic analysis
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Children with high-risk B-ALL with favorable cytogenetic features
Number of subjects: 1381
Study: 39121478

Group type: EXPERIMENTAL
Intervention: Automated SMS text message intervention, 2 daily messages for 4 weeks
Number of subjects: 30
Study: 39121557

Group type: EXPERIMENTAL
Intervention: Hyperammonemic crises (HA)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: EEG monitoring during HA events
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ammonia levels
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Glutamine levels
Number of subjects: 85
Study: 39121698

Group type: EXPERIMENTAL
Intervention: Booster dose of Ad26.COV2·S
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day 1 nAb levels against the Wuhan reference strain
Number of subjects: 0
Study: 39121849

Group type: EXPERIMENTAL
Intervention: Relatlimab (anti-LAG-3) plus Nivolumab (anti-PD-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab (anti-PD-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relatlimab (anti-LAG-3)
Number of subjects: 0
Study: 39121881

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (cALND)
Number of subjects: 1705

Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy only
Number of subjects: 1705
Study: 39121990

Group type: EXPERIMENTAL
Intervention: COMPASS-IBD online intervention for ∼12 weeks (including 6 × 30-min therapist sessions)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Routine mental health screening
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: COMPASS-IBD sessions completed
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Interviews with patients and healthcare providers
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Participant questionnaires at pre-intervention, 12-weeks (post-intervention), and 6-month follow-up
Number of subjects: 5000
Study: 39121992

Group type: EXPERIMENTAL
Intervention: Compassion microintervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training control
Number of subjects: 0